Table 2 Geometric mean fold rise (GMFR) from baseline of Anti-Spike IgG immune response against the Spike protein of SARS-CoV-2, and 50% neutralization titer (NT50) measured by pseudovirus neutralization assay (pNA) against SARS-CoV-2 ancestral and Omicron (XBB.1.5) strains in per protocol population and in subgroup of participants with hybrid immunity.
GMFR from Baseline | Ad26.COV2.S | ChAdOx1 | mRNA platform |
|---|---|---|---|
Total | |||
Anti-Spike IgG | |||
Day 28 | 6.62 (4.46–9.26), n = 57 | 7.81(6.07–10.06), n = 66 | 7.52 (5.81–9.73), n = 66 |
Day 90 | 3.36 (2.51–4.50), n = 57 | 4.04 (3.16–5.16), n = 66 | 4.37 (3.37–5.67), n = 65 |
NT50 Ancestral | |||
Day 28 | 6.55 (4.76–9.01), n = 57 | 7.40 (5.49–9.96), n = 66 | 8.45 (6.05–11.81), n = 66 |
Day 90 | 8.86 (7.42–10.57), n = 57 | 8.18 (6.24–10.72), n = 66 | 10.98 (7.87–15.32), n = 65 |
NT50 XBB.1.5 | |||
Day 28 | 13.04 (8.61–19.74), n = 57 | 20.94 (14.18–30.92), n = 66 | 29.16 (19.55–43.49), n = 66 |
Day 90 | 5.4 (3.74–7.78), n = 57 | 8.03 (5.07–12.71), n = 66 | 12.77 (8.53–19.09), n = 65 |
Hybrid group (N) | |||
Anti-Spike IgG | |||
Day 28 | 5.60 (3.68–8.54), n = 30 | 7.14 (5.20–9.80), n = 36 | 5.85 (4.47–7.65), n = 34 |
Day 90 | 2.96 (2.01–4.38), n = 30 | 3.56 (2.65–4.77), n = 36 | 3.52 (2.74–4.52), n = 33 |
NT50 Ancestral | |||
Day 28 | 5.59 (3.67–8.51), n = 30 | 6.93 (4.75–10.12), n = 36 | 5.99 (4.40–8.17), n = 34 |
Day 90 | 6.40 (4.15–9.86), n = 30 | 7.73 (5.42–11.02), n = 36 | 8.19 (6.15–10.92), n = 33 |
NT50 XBB.1.5 | |||
Day 28 | 13.42 (7.35–24.51), n = 30 | 18.91 (10.78–33.17), n = 36 | 32.49 (18.94–55.75), n = 34 |
Day 90 | 5.56 (3.09–10.01), n = 30 | 7.20 (3.80–13.64.80.64), n = 36 | 15.73 (9.20–26.89.20.89), n = 33 |
